Individuals and society. AR is Bendamustine 3543-75-7 characterized by inflammation of the nasal mucous membrane. Sneezing, runny nose, itchy nose and itchy eyes and palate occur following the release of inflammatory mediators such as histamine, leukotrienes, prostaglandin D 2, tryptase, and kinins. Histamine plays a role In the pathophysiology of RA through its neural and vascular Important Ren effects, which then only nasal itching, rhinorrhea and nasal obstruction. Treatment strategies for RA z Corticostéro choose By topical, oral or topical antihistamines, allergen-specific immunotherapy and other methods, including normal antihistamines are a cornerstone unerl Ugly, although the nasal spray stero should be the most effective between different types of nasal sprays. Compared with oral antihistamines, which are currently widely used for topical administration of antihistamines has the right to Naseng Length several advantages, including normal lower risk of systemic side effects and drug interactions. Azelastine nasal spray and levocabastine nasal spray products are currently on the hour Ufigsten used topical antihistamines in the treatment of seasonal allergic rhinitis. Both agents are m Possible and selective antagonist of H 1 receptor without significant affinity t in vitro to H 2, dopaminergic, adrenergic, serotonergic and cholinergic receptors. When intranasally, SNA and SLN have demonstrated that they are effective against itchy nose, sneezing and runny nose. There are two direct, prospective studies comparing the efficacy and reps Possibility of the two drugs. It is not surprising that both NLS and LNS effectively provided and well tolerated Possible symptomatic treatment of seasonal allergic rhinitis. SNA has been reported that statistically superior efficacy and safety in a 4-w Speaking of treatment, 180 patients w While LNS was considered at least as effective as but better than, END tolerated in a 1-w Speaking treatment of 123 patients . In the absence of direct comparison of these two topical antihistamines for the treatment of persistent AR is not yet done, the present study was initiated to compare the performance of an action, efficacy and reps Possibility of SNA either as monotherapy or SLN for moderate to severe persistent AR . Subjects and methods issues a total of 244 patients aged 18 years 65 years met the criteria for inclusion in this study. All subjects were required to have a history of at least 2 years of symptoms of moderate to severe mehrj Hrige AR, abh Have ngig of allergic rhinitis and its impact on asthma guidelines. Each subject had to have a positive skin test and ad be in good general health, such as k rperliche examination and clinical laboratory values. Exclusion criteria: seasonal allergic rhinitis, nonallergic rhinitis, nasal other diseases associated with the results of the upper respiratory tract infections, severe rhinostenosis the nnte from the deviation Moxifloxacin  186826-86-8 of the nasal septum, severe asthma interfere with the treatment with k other nose drops, nasal and oral antihistamines or vasoconstrictors in the last 7 days, severe heart disease, liver or kidney failure, pregnancy or lactation, hypersensitivity to azelastine or levocabastine, AIDS, venereal diseases, alcohol abuse or Alkoholabh dependence, and the planned operation may need during the study period. This study design.